Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure

Inclusion criteria

• Age range from 18 to 65 years old;
• Patients with acute liver failure in the early and intermediate stages caused by various reasons;
• Total bilirubin (TBil) ≥ 171μmol/L or an increase of ≥ 17.1μmol/L per day;
• Prothrombin activity (PTA) between 20% and 40% (or INR between 1.5 and 2.6);
• No hepatic encephalopathy or encephalopathy below grade II (including grade II);
• Elevated inflammatory markers (IL-6 / TNF-α / CRP, etc.);
• The subjects are able to communicate well with the researchers and can complete the study in accordance with the study regulations;
• The subjects must be informed of this study and voluntarily sign a written informed consent form before the experiment.

Exclusion criteria

• Patients with severe active bleeding or diffuse intravascular coagulation;
• Patients with a high degree of allergy to blood products or drugs used during treatment, such as plasma, heparin, and protamine;
• Patients with circulatory failure;
• Patients with a MELD score > 30;
• Patients with other severe heart diseases, lung diseases, blood diseases, autoimmune diseases, or diabetes;
• Subjects who may be unable to complete this study for other reasons or who the researchers believe should not be included.